NYSE: CATX
Perspective Therapeutics, Inc.CIK 0000728387 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade CATX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Perspective Therapeutics files routine corporate presentation update
2 material changes detected. Sign up free to read the summary.
Perspective Therapeutics holds routine annual meeting, elects six directors for one-year terms
3 material changes detected. Sign up free to read the summary.
Perspective Therapeutics to present interim clinical trial results at ASCO 2026
2 material changes detected. Sign up free to read the summary.
Perspective Therapeutics reports Q1 2026 financial results and business updates
2 material changes detected. Sign up free to read the summary.
net income -$26.2M. Perspective extends cash runway to late 2027, advances three clinical programs
5 material changes detected. Sign up free to read the summary.
Perspective Therapeutics discloses preliminary Q1 2026 cash position in analyst presentation
3 material changes detected. Sign up free to read the summary.
Perspective Therapeutics presents interim Phase 1/2a data for lead cancer drug VMT-α-NET
4 material changes detected. Sign up free to read the summary.
net income -$103.1M. Perspective advances VMT-α-NET to 6.0 mCi dose, extends runway to late 2027
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 10, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(Dollars and shares in thousands, except for per-share amounts)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Grant revenue | 81 | 290 | 157 | 632 |
| Operating expenses: | ||||
| Research and development | 21,544 | 16,620 | 42,916 | 30,952 |
| General and administrative | 7,795 | 7,709 | 14,780 | 15,551 |
| Total operating expenses | 29,339 | 24,329 | 57,696 | 46,503 |
| Operating loss | (29,258) | (24,039) | (57,539) | (45,871) |
| Non-operating income (expense): | ||||
| Interest income | 2,347 | 2,159 | 4,544 | 4,543 |
| Interest and other expense | (71) | (119) | (176) | (247) |
| Other income from a related party (Note 3) | - | - | - | 1,400 |
| Equity in loss of affiliate | (1) | - | (1) | (1) |
| Total non-operating income, net | 2,275 | 2,040 | 4,367 | 5,695 |
| Net loss from continuing operations | (26,983) | (21,999) | (53,172) | (40,176) |
| Net gain from discontinued operations | 197 | 514 | 197 | 514 |
| Net loss before deferred income tax benefit | (26,786) | (21,485) | (52,975) | (39,662) |
| Deferred income tax benefit | - | - | - | - |
| Net loss | (26,786) | (21,485) | (52,975) | (39,662) |
| Basic and diluted loss per share: | ||||
| Loss from continuing operations | (0.22) | (0.30) | (0.47) | (0.55) |
| Gain from discontinued operations | - | 0.01 | - | 0.01 |
| Basic and diluted loss per share | (0.22) | (0.29) | (0.47) | (0.54) |
| Weighted average number of shares used in computing net loss per share: | ||||
| Basic and diluted | 120,651 | 74,235 | 112,174 | 73,301 |
| Unrealized gain (loss) on available-for-sale securities | 5 | (16) | (331) | 54 |
| Comprehensive loss | (26,781) | (21,501) | (53,306) | (39,608) |
Condensed Consolidated Balance Sheets
(In thousands, except shares and par value data)
| Description | June 30, 2026 (unaudited) | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 48,488 | 30,629 |
| Short-term investments | 188,388 | 114,108 |
| Accounts receivable, net of allowance for doubtful accounts: $375 for each period | 269 | 6 |
| Prepaid expenses and other current assets | 4,378 | 3,646 |
| Total current assets | 241,523 | 148,389 |
| Noncurrent assets: | ||
| Property and equipment, net | 107,797 | 76,597 |
| Right-of-use asset | 2,196 | 1,500 |
| Intangible assets, in-process research and development | 40,000 | 40,000 |
| Other assets | 509 | 486 |
| Total assets | 392,025 | 266,972 |
| LIABILITIES AND STOCKHOLDERSʼ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | 29,418 | 20,511 |
| Lease liability | 1,097 | 623 |
| Accrued personnel expenses | 5,972 | 7,489 |
| Note payable | 57 | 56 |
| Total current liabilities | 36,544 | 28,679 |
| Noncurrent liabilities: | ||
| Lease liability, net of current portion | 1,269 | 1,005 |
| Note payable, net of current portion | 1,540 | 1,569 |
| Deferred Income (Note 3) | 26,600 | 26,600 |
| Deferred tax liability | 1,702 | 1,702 |
| Other noncurrent liabilities | 507 | 386 |
| Total liabilities | 68,162 | 59,941 |
| Commitments and contingencies (Note 10) | ||
| Stockholdersʼ equity: | ||
| Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000 designated Series B convertible; no shares issued | - | - |
| Common stock: $0.001 par value; 750,000,000 shares authorized; 114,086,092 and 74,337,990 shares issued | 114 | 74 |
| Additional paid-in capital | 711,785 | 541,687 |
| Accumulated other comprehensive (loss) income | (221) | 110 |
| Accumulated deficit | (387,815) | (334,840) |
| Total stockholdersʼ equity | 323,863 | 207,031 |
| Total liabilities and stockholdersʼ equity | 392,025 | 266,972 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(In thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | (52,975) | (39,662) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Net accretion of discounts on available-for-sale securities | (1,151) | (1,765) |
| Depreciation and amortization expense | 2,267 | 1,465 |
| Share-based compensation | 5,599 | 4,501 |
| Other noncash income, net | 114 | 222 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (263) | (109) |
| Interest receivable | (250) | (286) |
| Prepaid expenses and other current assets | (482) | 259 |
| Accounts payable and accrued expenses | (3,581) | (4,548) |
| Deferred Income1 | - | (1,400) |
| Accrued personnel expenses | (1,517) | (441) |
| Other noncurrent liabilities | 121 | 229 |
| Net cash used in operating activities | (52,118) | (41,535) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Additions to property and equipment | (21,053) | (5,682) |
| Additions to other assets | (21) | (45) |
| Purchases of available-for-sale securities | (185,952) | (67,094) |
| Maturities of available-for-sale securities | 112,492 | 71,520 |
| Net cash used in investing activities | (94,534) | (1,301) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Repayment of note payable | (28) | (26) |
| Proceeds from sales of common stock pursuant to exercise of options | 450 | 145 |
| Proceeds from the sale of common stock pursuant to at-the-market offering, net1 | - | 9,986 |
| Proceeds from issuance of common stock and Pre-funded Warrants, net1 | 164,089 | - |
| Net cash provided by financing activities | 164,511 | 10,105 |
| Net increase (decrease) in cash and cash equivalents | 17,859 | (32,731) |
| Cash and cash equivalents at beginning of period | 30,629 | 61,580 |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | 48,488 | 28,849 |
| Supplemental schedule of noncash investing and financing activities: | ||
| Additions to property and equipment in accounts payable and accrued expenses | 12,411 | 1,058 |
| Recognition of operating lease liability and right-of-use asset | 1,250 | - |
Amounts as printed on the EDGAR/iXBRL face — (Dollars and shares in thousands, except for per-share amounts); (In thousands, except shares and par value data); (In thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗